Cancer Institute NSW

Changes relating to the 2022 NSW cancer incidence and mortality dataset

Version 1.0, March 2025

NSW GOVERNMENT

Publisher:

Cancer Institute NSW
Level 4, 1 Reserve Road,
St Leonards, NSW 2065

Locked Bag 2030 St Leonards NSW 1590

Tel: (02) 8374 5600
Email: information@cancer.nsw.gov.au
Web: cancer.nsw.gov.au

Suggested Citation

Cancer Institute NSW. Changes relating to the 2022 NSW cancer incidence and mortality dataset. Sydney: Cancer Institute NSW, 2025.

Copyright

Record number: E25/05297

Contents

1. Summary

1.1. Date updated

31 March 2025

1.2. Dataset

NSW Cancer Registry (NSWCR) - 2022 NSW cancer incidence and mortality dataset

1.3. Release summary

This dataset release incorporates updates to data, new data elements, renaming of data elements & removal of data elements as summarised below:

- Data updates:

  — Rare non-melanoma skin cancers have been included.

  — Death data from 1982 to 2019 have been updated using a matching process to the National Death Index (NDI).

  — Remoteness data elements have been updated to use the Australian Statistical Geography Standard (ASGS) Edition 3. Edition 3 was based on the 2021 Australian Bureau of Statistics (ABS) census.

  — Socioeconomic position data elements have been updated to use the ASGS Edition 3.

  — The in situ cancer case extraction method has changed from using the International Classification of Diseases 9th revision (ICD-9) to ICD-10.

- New data elements:

  — Cancer types and clinical cancer groups using the ICD-10 (version 2019).

  — Geographical boundaries using ASGS Edition 3.

  — Local government area (LGA) 2022 and 2023.

  — Local health district (LHD) version 2011.

  — Name/description included for relevant data elements.

- Removed data elements:

  — ICD-10 AM data elements are no longer provided.

- Some data elements have been renamed for consistency.

2. Data updates

2.1. Inclusion of rare non-melanoma skin cancer

The latest dataset release now includes rare non-melanoma skin cancer types such as Merkel cell carcinoma and angiosarcoma. Common non-melanoma skin cancer types of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are still excluded (ICD-10 code "C44" with 805-811 morphologies). The inclusion of these has changed the overall statistics as outlined below.

In the last five years of available data from 2018-2022, incidence and mortality 'all cancer' statistics increased by an average of 1.1% and 0.4% respectively due to the inclusion of rare non-melanoma skin cancer (Table 1).

Table 1: Non-melanoma skin cancer incidence and mortality, 2018-2022

Incidence/mortality	Number of cases/deaths		
	All cancers (#)	Non-melanoma skin cancer (#)	Non-melanoma skin cancer (%)
Incidence	247,143	2,666	1.1
Mortality	77,632	327	0.4

Skin cancer clinical group case numbers have increased by almost 10%, due to the inclusion of rare non-melanoma skin cancers (Table 2).

Table 2: Impact of inclusion of non-melanoma skin cancer on clinical cancer group, 2018-2022

Clinical cancer group	Number of cases			
	ICD-9	ICD-10 (2019)	Difference (#)	Difference (%)
Skin	27,329	29,991	2,662	9.7

2.2. Death data NDI update

2.2.1. Background

The National Death Index (NDI) is a Commonwealth database developed and maintained by the Australian Institute of Health and Welfare (AIHW). It contains all deaths in Australia since 1980, sourced from the Registrars of Births, Deaths and Marriages in each jurisdiction, the National Coronial Information System and the ABS.

Records for people alive on the Australian Cancer Database (ACD) held by the AIHW who were diagnosed with cancer between 1982 and 2019 have undergone a matching process against the records in the NDI. These data have been used to update the NSW Cancer Registry (NSWCR) death data. This process identifies people who were diagnosed with cancer in NSW but have since moved interstate and died, or people who have died of causes other than cancer.

2.2.2. Use of NSWCR data for reporting survival

The current release data are complete for reporting survival (of any type) for people who were diagnosed with cancer in NSW between **1982** and **2019** with deaths followed up to **2019**.

2.2.3. Change analysis

The NDI death data update led to an increase in recorded deaths overall of 5.2% between 1982 and 2019, of which 1.3% were cancer deaths and 14.8% were non-cancer deaths (Table 3). Note: these results exclude rare non-melanoma skin cancer to show the impact of the NDI death update alone.

Table 3: Impact of NDI death data update on the number of deaths, by cause of death, 1982-2019

Cause of death	Total deaths	NDI matched deaths (#)	NDI matched deaths (%)
Cancer death	473,393	6,253	1.3
Non-cancer death	190,426	28,258	14.8
Unknown cause of death	5,310	35	0.7
All deaths	669,129	34,546	5.2

The NDI update primarily impacted deaths from 2009 to 2019, leading to an increase in overall deaths of 13%, of which 3.5% were cancer deaths and 31.1% were non-cancer deaths (Table 4).

Table 4: Impact of NDI death data update on the number of deaths, by cause of death, 2009-2019

Cause of death	Total deaths	NDI matched deaths (#)	NDI matched deaths (%)
Cancer death	162,299	5,726	3.5
Non-cancer death	86,046	26,777	31.1
Unknown cause of death	917	0	0.0
All deaths	249,262	32,503	13.0

The change in number of cancer and non-cancer deaths between the previous and current datasets is shown in Chart 1 below.

Chart 1: Impact of NDI death data update, by cause of death, 1982-2019

2.3. Remoteness

Remoteness for cases diagnosed from 2011 onwards is derived from remoteness classes at Statistical Area 1 (SA1) level, using the logic below:

- Diagnosis year 2011 to 2013 → SA1 2011 remoteness classes
- Diagnosis year 2014 to 2018 → SA1 2016 remoteness classes
- Diagnosis year 2019 onwards → SA1 2021 remoteness classes

In the previous dataset release, SA1 2016 was used for cases diagnosed from 2014 to 2021, however, in the current dataset release cases from 2019 onwards have been revised using SA1 2021. This logic change impacts the remoteness class related data elements (Table 5).

Table 5: Data elements impacted by the change in remoteness logic

Data dictionary item no.	Data dictionary name	Dataset variable name/s
59.	Remoteness (ASGC, ASGS)	RemotenessCode RemotenessName
60.	Remoteness calculation method	RemotenessCalcMethod

The remoteness class assigned historically may have changed, with major cities and inner regional cases increasing by 0.6% and 3.8% respectively, and outer regional cases decreasing by 17.9% between 2019 and 2021 (Table 6). Note: these results exclude rare non-melanoma skin cancer and changes to case counts between dataset releases to show the impact of the remoteness change alone.

Table 6: Impact of logic change on the number of cases, by remoteness class, 2019-2021

Remoteness class	2021 dataset	2022 dataset	Difference (#)	Difference (%)
Major cities	98,373	98,951	578	0.6
Inner regional	35,500	36,835	1,335	3.8
Outer regional	10,791	8,863	-1,928	-17.9
Remote/very remote	733	733	0	0.0
Unknown	38	53	15	39.5

For further information about the remoteness classes and structure see the link below:

https://www.abs.gov.au/statistics/standards/australian-statistical-geography-standard-asgs-edition-3/jul2021-jun2026/remoteness-structure

2.4. Socioeconomic position

Socioeconomic position deciles and quintiles for cases diagnosed from 2011 onwards are derived from indices using Statistical Area 1 (SA1) following the logic below. Note: there are two types of indices available, one is based on the index of relative socioeconomic disadvantage (IRSD) and the other is based on the index of relative socioeconomic advantage and disadvantage (IRSAD).

- Diagnosis year 2011 to 2013 → SA1 2011 deciles/quintiles
- Diagnosis year 2014 to 2018 → SA1 2016 deciles/quintiles
- Diagnosis year 2019 onwards → SA1 2021 deciles/quintiles

In the previous dataset release, SA1 2016 was used for cases diagnosed from 2014 to 2021, however, in the current dataset release cases from 2019 onwards have been revised using SA1 2021. This logic change impacts the socioeconomic position related data elements (Table 7).

Table 7: Data elements impacted by the change in socioeconomic position logic

Data dictionary item no.	Data dictionary name	Dataset variable name/s
61.	Socioeconomic position - IRSAD deciles (ASGC, ASGS)	SEIFAIRSADDecileCode SEIFAIRSADDecileName SEIFAIRSADDecileDescription
62.	Socioeconomic position - IRSAD quintiles (ASGC, ASGS)	SEIFAIRSADQuintileCode SEIFAIRSADQuintileName SEIFAIRSADQuintileDescription
63.	Socioeconomic position - IRSD deciles (ASGC, ASGS)	SEIFAIRSDDecileCode SEIFAIRSDDecileName SEIFAIRSDDecileDescription
64.	Socioeconomic position - IRSD quintiles (ASGC, ASGS)	SEIFAIRSDQuintileCode SEIFAIRSDQuintileName SEIFAIRSDQuintileDescription

Data dictionary item no.	Data dictionary name	Dataset variable name/s
65.	Socioeconomic position calculation method	SEIFACalcMethod

The socioeconomic position assigned may have changed historically. For the IRSD, quintile 2 cases increased by 3.4% and quintile 4 cases decreased by 2.2% between 2019 and 2021 (Table 8). Note: these results exclude rare non-melanoma skin cancer and changes to case counts between dataset releases to show the impact of the socioeconomic position change alone.

Table 8: Impact of logic change on the number of cases, by socioeconomic position IRSD quintiles, 2019-2021

Socioeconomic position IRSD quintile	2021 dataset	2022 dataset	Difference (#)	Difference (%)
Quintile 1 (most disadvantaged)	32,263	31,973	-290	-0.9
Quintile 2	30,400	31,426	1,026	3.4
Quintile 3	28,294	28,389	95	0.3
Quintile 4	27,010	26,428	-582	-2.2
Quintile 5 (least disadvantaged)	26,913	26,747	-166	-0.6
Unknown	555	472	-83	-15.0

For further information about the socioeconomic position indices see the link below:

https://www.abs.gov.au/statistics/people/people-and-communities/socio-economic-indexes-areas-seifa-australia/2021

2.5. In situ cancer case extraction method

The previous dataset release used ICD-9 codes to define melanoma (C43) and breast cancer (C50) in situ cancer cases. The latest dataset release now uses ICD-10 version 2019 codes (still C43 & C50) to identify them.

The impact on in situ cancer case numbers is minimal with a small number of cases (147) now being classified as melanoma in situ (D03.8 melanoma in situ of other sites), leading to an overall increase of 0.1% of all notified in situ cancer cases (Table 9).

Table 9: Impact of logic change on the number of in situ cancer cases, by cancer type and ICD code, 2002-2022

ICD-10 code	ICD-9 code	In situ cancer cases (#)	Percentage of all in situ cancer cases (%)
Breast cancer (C50)	Breast cancer (C50)	17,487	11.5
Melanoma of skin (C43)	Melanoma of skin (C43)	134,979	88.4
	Other ICD-9 codes (not C43 or C50)	147	0.1

3. New data elements

3.1. ICD-10 (version 2019) diagnosis and death codes

New ICD-10 data elements based on version 2019 are available in this dataset release (Table 10). The new ICD-10 code will replace the previous ICD-10-AM topography code. The new ICD-10 based cancer type and clinical group data elements have been created to provide the latest ICD-10 version and updated cancer groupings that represent current Australian definitions. [1,2,3]

Table 10: New ICD-10 (version 2019) data elements

Data dictionary item no.	Data dictionary name	Dataset data element name/s
18.	ICD-10 code (2019)	DiagnosisICD10Rep2Code
19.	Cancer type ICD-10 (2019)	DiagnosisICD10GrpCode DiagnosisICD10GrpName
20.	Clinical cancer group ICD-10 (2019)	DiagnosisClinicalCancerGrp2Code DiagnosisClinicalCancerGrp2Name
40.	Cause of death ICD-10 code (2019)	DeathICD10Rep2Code
41.	Cause of death cancer type ICD-10 (2019)	DeathICD10GrpCode DeathICD10GrpName
42.	Cause of death clinical cancer group ICD-10 (2019)	DeathClinicalCancerGrp2Code DeathClinicalCancerGrp2Name

3.1.1. Cancer type and clinical cancer group changes

The previous dataset release contained cancer types and clinical cancer groups based on the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) recoded to follow ICD-9 groupings developed by the Cancer Institute NSW for incidence and mortality reporting. The current dataset release has new cancer types and clinical cancer groups, still based on ICD-O-3 but now recoded to ICD-10 version 2019 codes and regrouped to reflect the most commonly used definitions in Australian incidence and mortality reporting (Table 10). [1,2,3]

The corresponding ICD-9 and ICD-10 data elements are shown in Table 11 below.

Table 11: Cancer type and clinical cancer group data elements for ICD-9 and ICD-10 (version 2019)

Data dictionary name		Dataset data element name/s	
ICD-9	ICD-10 (2019)	ICD-9	ICD-10 (2019)
Cancer type ICD-9	Cancer type ICD-10 (2019)	DiagnosisICD9GrpTopoCode DiagnosisICD9GrpTopoName	DiagnosisICD10GrpCode DiagnosisICD10GrpName
Clinical cancer group ICD-9	Clinical cancer group ICD-10 (2019)	DiagnosisClinicalCancerGrp1Code DiagnosisClinicalCancerGrp1Name	DiagnosisClinicalCancerGrp2Code DiagnosisClinicalCancerGrp2Name

Data dictionary name		Dataset data element name/s	
ICD-9	ICD-10 (2019)	ICD-9	ICD-10 (2019)
Cause of death cancer type ICD-9	Cause of death cancer type ICD-10 (2019)	DeathICD9GrpTopoCode DeathICD9GrpTopoName	DeathICD10GrpCode DeathICD10GrpName
Cause of death clinical cancer group ICD-9	Cause of death clinical cancer group ICD-10 (2019)	DeathClinicalCancerGrp1Code DeathClinicalCancerGrp1Name	DeathClinicalCancerGrp2Code DeathClinicalCancerGrp2Name

For a summary of the coding changes between versions and the full list of the ICD-9 and ICD-10 (2019) cancer types and clinical cancer groups with code groups and definitions, refer to The Appendices (links are below):

- [Table A1: Cancer type coding changes](#)
- [Table A2: Clinical cancer group coding changes](#)
- [Table A3: Cancer type ICD-10 (2019)](#)
- [Table A4: Clinical cancer group ICD-10 (2019)](#)
- [Table A5: Cancer type ICD-9](#)
- [Table A6: Clinical cancer group ICD-9](#)

3.1.2. Cancer type and clinical group name changes

Some cancer type and clinical cancer group names have been revised between the ICD-9 and ICD-10 versions (Table 12).

Table 12: Cancer type and clinical cancer group name changes

Cancer type/clinical cancer group	ICD-9 name	ICD-10 (2019) name
Cancer type	Non-Hodgkins lymphoma	Non-Hodgkin lymphoma
	Other lymphoid leukaemias	Other and unspecified lymphoid leukaemias
	Other myeloid leukaemias	Other and unspecified myeloid leukaemias
	Cancer unknown primary	Cancer of unknown primary
	Central nervous system	Other central nervous system
Clinical cancer group	Lymphohaematopoietic	Blood cancers
	Cancer unknown primary	Ill-defined sites and unknown primary sites

3.1.3. Cancer type definition changes

The update of ICD-10 (2019) coding and revision of cancer type groupings has meant that some existing cancer types have changed definitions, new cancer types have been created, and others have been removed. Existing cancer types impacted by this change are rectal, ovarian, cancer of unknown primary, other endocrine, other central nervous system, and several blood cancer types. The impact on cancer case numbers for 2018-2022 is shown in Table 13 below. Tables 14 and 15 show the number of cancer cases for new and removed cancer types respectively.

Rectal cancer cases have decreased by 10% due to the removal of anal cancer, which is now available as a new cancer type.

There is some minor movement in case numbers from ovarian (-0.4%) to other female genital cancers (+1.3%), due to the reclassification of most fallopian tube cancers. Ovarian cancer now consists of cancer of the ovary and high-grade serous carcinomas of the fallopian tube only.

There is moderate movement in case numbers from 'other endocrine gland' (-27.2%) to 'other central nervous system (CNS) cancers' (+63.0%), due to the reallocation of endocrine gland cancers of the cranial cavity.

Cancer of unknown primary has decreased by 22%, due to the removal of 'other and ill-defined sites', and peritoneal cancers. These two groups are now available as new cancer types.

Significant change occurred for multiple blood cancer types. This is primarily due to the creation of new blood cancer types and the reallocation of new ICD-O-3.2 codes:

- Non-Hodgkin lymphoma has decreased by 5.1%, predominantly due to the movement of morphology code 976 (immunoproliferative diseases) to a new immunoproliferative cancer type (C88).

- Multiple myeloma has decreased by 1.0% due to the reclassification of new ICD-O-3.2 morphology codes 9735, 9737 and 9738 to Non-Hodgkin lymphoma.

- Acute lymphoblastic leukaemia (ALL) has increased almost two-fold (+180.5%). This is due to the movement of new ICD-O-3.2 morphology code 981 (B lymphoblastic leukaemia/lymphoma) from the now redundant 'other lymphatic haematopoietic' cancer to ALL.

- Other and unspecified lymphoid leukaemia has decreased by 92.7% due to the creation of chronic lymphocytic leukaemia (CLL).

- Acute myeloid leukaemia (AML) has increased by 3.5%, due to the inclusion of new ICD-O-3.2 morphology codes (9865, 9869, 9877, 9878, 9879, 9898) that were previously coded to 'other lymphatic haematopoietic' cancer.

- Other and unspecified myeloid leukaemia has decreased by 98.5%, due to the creation of chronic myeloid leukaemia (CML) and chronic myelomonocytic leukaemia (CMML).

- Myeloproliferative neoplasms (excluding. CML) have been created from morphology codes that were part of the now redundant 'other lymphatic haematopoietic' cancer type.

Table 13: Impact of change in cancer type from ICD-9 to ICD-10 on number of cases, 2018-2022

Cancer type	Number of cases			
	ICD-9	ICD-10 (2019)	Difference (#)	Difference (%)
Rectal	8,788	7,906	-882	-10.0
Ovarian	3,000	2,988	-12	-0.4
Other female genital	897	909	12	1.3
Other central nervous system	189	308	119	63.0
Other endocrine gland	437	318	-119	-27.2
Cancer of unknown primary	5,418	4,222	-1,196	-22.1
Non-Hodgkin lymphoma	10,348	9,822	-526	-5.1
Multiple myeloma	3,645	3,609	-36	-1.0

Cancer type	Number of cases			
	ICD-9	ICD-10 (2019)	Difference (#)	Difference (%)
Acute lymphoblastic leukaemia	261	732	471	180.5
Other and unspecified lymphoid leukaemias	3,525	258	-3,267	-92.7
Acute myeloid leukaemia	1,964	2,032	68	3.5
Other and unspecified myeloid leukaemias	1,196	18	-1,178	-98.5

Table 14: Number of cases for new ICD-10 cancer types, 2018-2022

Cancer type ICD-10	Number of cases (#)	Percentage of cases (%)
Anal (C21)	882	0.4
Other and ill-defined (C237)	869	0.4
Retroperitoneum and peritoneum (C48)	327	0.1
Immunoproliferative (C88)	546	0.2
Chronic lymphocytic leukaemia (C911)	3,436	1.4
Chronic myeloid leukaemia (C921)	659	0.3
Chronic myelomonocytic leukaemia (C931)	516	0.2
Other and unspecified leukaemias (C945)	234	0.1
Other blood cancers (C96)	127	0.1
Myeloproliferative neoplasms (excluding CML) (D457)	2,193	0.9

Table 15: Number of cases for removed cancer types (ICD-9), 2018-2022

Cancer type ICD-9	Number of cases (#)	Percentage of cases (%)
Other lymphatic haematopoietic (ICD-9 M95)	2,814	1.1
Other specified leukaemias (ICD-9 C94)	169	0.1
Unspecified leukaemias (ICD-9 C95)	234	0.1

These coding changes are shown in more detail in Appendix Table A1: Cancer type coding changes.

3.1.4. Clinical cancer group definition changes

The update of ICD-10 (2019) coding has meant that some clinical cancer groups have changed definitions, one new grouping has been created, and one has been removed. Existing clinical cancer groups impacted by this change are blood, bowel, skin, and ill-defined and unknown primary sites

(previously described as 'Cancer of unknown primary'). The impact on cancer case numbers for 2018-2022 is shown in Table 16 below. Tables 17 and 18 contain the number of cancer cases for new and removed clinical cancer groups respectively.

There is a negligible change in blood cancer clinical group case numbers, which have slightly increased by 0.1%.

Bowel cancer clinical group case numbers have decreased by 3.4%, due to the removal of anal cancer now part of the new "all other" clinical cancer group.

Ill-defined and unknown primary site (formerly "cancer of unknown primary") case numbers have decreased by 6.0% due to the removal of peritoneal cancers now part of the new "all other" clinical cancer group.

The eye cancer clinical group has been removed and the cases included in the new "all other" clinical cancer group.

Table 16: Impact of change in clinical cancer group from ICD-9 to ICD-10 on the number of cases, 2018-2022

Clinical cancer group	Number of cases			
	ICD-9	ICD-10 (2019)	Difference (#)	Difference (%)
Blood cancers	27,866	27,888	22	0.1
Bowel	25,621	24,739	-882	-3.4
Ill-defined sites and unknown primary sites	5,418	5,091	-327	-6.0

Table 17: Number of cases for new clinical cancer group (ICD-10), 2018-2022

Clinical cancer group ICD-10	Number of cases (#)	Percentage of cases (%)
All other	1,698	0.7

Table 18: Number of cases for removed clinical cancer group (ICD-9), 2018-2022

Clinical cancer group ICD-9	Number of cases (#)	Percentage of cases (%)
Eye	489	0.2

These coding changes are shown in more detail in Appendix Table A2: Clinical cancer group coding changes.

3.2. ASGS 2021 geographical boundaries

This dataset release contains new geographical boundary data elements updated to reflect the latest ASGS Edition 3 (Table 19). Edition 3 was based on the 2021 ABS census.

Table 19: New ASGS Edition 3 (2021) data elements

Data dictionary item no.	Data dictionary name	Dataset data element name/s
52.	LGA 2021 (ASGS)	GCDiagnosisLGACode2021 GCDiagnosisLGAName2021 GCDiagnosisLGADescription2021
53.	SA2 2021 (ASGS)	GCDiagnosisSA2Code2021 GCDiagnosisSA2Name2021
54.	SA3 2021 (ASGS)	GCDiagnosisSA3Code2021 GCDiagnosisSA3Name2021
55.	SA4 2021 (ASGS)	GCDiagnosisSA4Code2021 GCDiagnosisSA4Name2021
56.	GCCSA 2021 (ASGS)	GCDiagnosisGCCSACode2021 GCDiagnosisGCCSAName2021

Further information about the ASGS Edition 3 (2021) release can be found below:

https://www.abs.gov.au/statistics/standards/australian-statistical-geography-standard-asgs-edition-3/jul2021-jun2026

3.2.1. Changes to LGA between ASGS 2016 and ASGS 2021

There have been some changes to LGA boundaries, codes and names between ASGS releases as detailed in Table 20 below.

Table 20: Changes to LGAs between ASGS 2016 and ASGS 2021

LGA 2016	LGA 2021	Ratio	Change description
10130 Armidale Regional	10180 Armidale Regional	0.9703365	LGA boundary change & change to code.
	14220 Inverell	0.0296635	
10750 Blacktown	10750 Blacktown	0.999982	LGA boundary change.
	12380 Cumberland	0.000018	
11100 Botany Bay	10500 Bayside	N/A	Merge of Botany Bay and Rockdale LGAs to form Bayside LGA.
11450 Camden	11450 Camden	0.9999408	LGA boundary change.
	11500 Campbelltown	0.0000592	
11500 Campbelltown	11450 Camden	0.0004083	LGA boundary change.
	11500 Campbelltown	0.9995917	
11750 Cobar	11750 Cobar	0.9793109	LGA boundary change.
	14600 Lachlan	0.0206891	
12380 Cumberland	12380 Cumberland	0.9999886	LGA boundary change.

LGA 2016	LGA 2021	Ratio	Change description
	16260 Parramatta	0.0000114	
13510 Gundagai	12160 Cootamundra-Gundagai Regional	N/A	Changed code and name.
14200 Inverell	14220 Inverell	N/A	LGA boundary change & change to code.
16650 Rockdale	10500 Bayside	N/A	Merge of Botany Bay and Rockdale LGAs.to form Bayside LGA.
18230 Western Plains Regional	12390 Dubbo Regional	N/A	Changed code and name.

The impact of the changes to LGA boundaries were minor overall as shown in Table 21 below. Notable changes occurred to Armidale Regional and Inverell LGAs where case numbers decreased by 4.3% and increased by 6.4% respectively, due to a boundary realignment between the two LGAs. The other significant change was the merge of Botany Bay and Rockdale LGAs to form Bayside LGA. Note: these results exclude rare non-melanoma skin cancer to show the impact of the boundary change alone.

Table 21: Impact of LGA boundary changes on number of cases, 2018-2022

LGA	Number of cases (2018-2022)			
	ASGS 2016	ASGS 2021	Difference (#)	Difference (%)
10180 Armidale Regional	975	933	-42	-4.3
10750 Blacktown	8,030	8,029	-1	0.0
11100 Botany Bay	1,276	N/A	-1,276	-100.0
10500 Bayside (NSW)	N/A	4,411	4,411	100.0
11450 Camden	2,392	2,397	5	0.2
11500 Campbelltown (NSW)	4,393	4,389	-4	-0.1
11750 Cobar	119	116	-3	-2.5
12380 Cumberland	4,361	4,362	1	0.0
14220 Inverell	656	698	42	6.4
14600 Lachlan	254	254	0	0.0
16260 Parramatta	5,444	5,445	1	0.0
16650 Rockdale	3,135	N/A	-3,135	-100.0

3.3. LGA 2022 and LGA 2023

This data release contains new local government area (LGA) data elements for versions 2022 and 2023 which are based on an ABS mapping from Mesh Block version 2021 (Table 22).

There were no changes to LGAs between version 2021 and 2022/2023. Further information can be found below:

https://www.abs.gov.au/statistics/standards/australian-statistical-geography-standard-asgs-edition-3/jul2021-jun2026/non-abs-structures/local-government-areas#history-of-changes

Table 22: New LGA 2022 and 2023 data elements

Data dictionary item no.	Data dictionary name	Dataset variable name/s
57.	LGA 2022 (ASGS)	GCDiagnosisLGACode2022 GCDiagnosisLGAName2022
58.	LGA 2023 (ASGS)	GCDiagnosisLGACode2023 GCDiagnosisLGAName2023

3.4. Local health district (LHD) 2011

A new updated LHD boundary is available in this data release (Table 23). It is named version 2011 but was released in July 2023 by the Centre for Epidemiology and Evidence via the Secure Analytics for Population Health Research and Intelligence (SAPHaRI).

Table 23: New LHD 2011 data elements

Data dictionary item no.	Data dictionary name	Dataset variable name/s
67.	Local health district 2011	GCDiagnosisLHDCode2011 GCDiagnosisLHDName2011 GCDiagnosisLHDDescription2011

Changes between the two versions are negligible and due to a minor re-alignment of boundaries (Table 24). Note these results exclude rare non-melanoma skin cancer to show the impact of the boundary change alone.

Table 24: Impact of LHD boundary changes on number of cases. 2018-2022

| Local health district 2011 | Number of cases (2018-2022) | | | |
	LHD 2010	LHD 2011	Difference (#)	Difference (%)
Sydney LHD	15,765	15,765	0	0.0
South Western Sydney LHD	25,887	25,882	-5	0.0
South Eastern Sydney LHD	25,953	25,947	-6	0.0
Illawarra Shoalhaven LHD	15,101	15,099	-2	0.0
Western Sydney LHD	22,234	22,233	-1	0.0
Nepean Blue Mountains LHD	10,987	10,987	0	0.0
Northern Sydney LHD	27,311	27,313	2	0.0

Local health district 2011	Number of cases (2018-2022)			
	LHD 2010	LHD 2011	Difference (#)	Difference (%)
Central Coast LHD	13,072	13,069	-3	0.0
Hunter New England LHD	34,780	34,789	9	0.0
Northern NSW LHD	12,719	12,718	-1	0.0
Mid North Coast LHD	10,336	10,336	0	0.0
Southern NSW LHD	7,977	7,977	0	0.0
Murrumbidgee LHD	11,216	11,215	-1	0.0
Western NSW LHD	9,993	9,989	-4	0.0
Far West LHD	1,070	1,070	0	0.0
NSW Unknown LHD	76	88	12	15.8%

3.5. Name and description data elements

The previous data release contained code values only for most data elements. This data release contains the code as well as the name and description for each data element which will aid in analysis without the need to apply data formats (Table 25).

Table 25: New name and description data elements

Data dictionary item no.	Data dictionary name	Dataset variable name/s
1.	Sex	SexCode SexDescription
2.	Country of birth	CountryBirthName
3.	Aboriginal and Torres Strait Islander status	AboriginalityName
7.	Date of birth validity code	BirthDateValidityName
12.	Date of diagnosis validity code	DiagnosisDateValidityName
14.	Cancer type ICD-9	DiagnosisICD9GrpTopoName
15.	Clinical cancer group ICD-9	DiagnosisClinicalCancerGrp1Name
17.	Topography code 4 character (ICD-O-3)	DiagnosisICDO3TopoName4
23.	Behaviour code	DiagnosisBehaviourName DiagnosisBehaviourDescription
24.	Best basis of diagnosis	DiagnosisBasisGroupName
25.	Degree of spread at diagnosis	ExtentGroup2Name ExtentGroup2Description
26.	Laterality	LateralityCode

Data dictionary item no.	Data dictionary name	Dataset variable name/s
36.	Cause of death cancer type ICD-9	DeathICD9GrpTopoName
37.	Cause of death clinical cancer group ICD-9	DeathClinicalCancerGrp1Name
39.	Cause of death topography code 4 character (ICD-O-3)	DeathICDO3TopoName4
43.	Place of death group	PlaceDeathGroupName
45.	LGA 2006 (ASGC)	GCDiagnosisLGAName2006 GCDiagnosisLGADescription2006
46.	SLA 2006 (ASGC)	GCDiagnosisSLAName2006
47.	LGA 2016 (ASGS)	GCDiagnosisLGADescription2016
51.	GCCSA 2016 (ASGS)	GCDiagnosisGCCSACode2016
59.	Remoteness (ASGC, ASGS)	RemotenessName
61.	Socioeconomic position - IRSAD deciles (ASGC, ASGS)	SEIFAIRSADDecileName SEIFAIRSADDecileDescription
62.	Socioeconomic position - IRSAD quintiles (ASGC, ASGS)	SEIFAIRSADQuintileName SEIFAIRSADQuintileDescription
63.	Socioeconomic position - IRSD deciles (ASGC, ASGS)	SEIFAIRSDDecileName SEIFAIRSDDecileDescription
64.	Socioeconomic position - IRSD quintiles (ASGC, ASGS)	SEIFAIRSDQuintileName SEIFAIRSDQuintileDescription

4. Retired data elements

4.1. ICD-10-AM diagnosis and death codes

The previous ICD-10-AM codes have been replaced with new ICD-10 WHO version 2019 codes in this data release (Table 26).

Table 26: Removed data elements

Data dictionary name	Dataset variable name
Topography code (ICD-10-AM)	DiagnosisICD10RepTopoCode
Cause of death topography code (ICD-10-AM)	DeathICD10RepTopoCode

5. Renamed data elements

Some data elements have been renamed in the data dictionary or dataset variable names (Table 27).

Table 27: Renamed data elements

Data dictionary name		Dataset variable name	
2021 dataset	2022 dataset	2021 dataset	2022 dataset
Cancer type	Cancer type ICD-9	DiagnosisICD9GrpTopoCode	*No change*
Clinical cancer group	Clinical cancer group ICD-9	DiagnosisClinicalCancerGroupCode	DiagnosisClinicalCancerGrp1Code
Behaviour code	*No change*	BehaviourCode	DiagnosisBehaviourCode
Best basis of diagnosis	*No change*	DiagnosisBasisCode	DiagnosisBasisGroupCode
Cause of death cancer type	Cause of death cancer type ICD-9	DeathICD9GrpTopoCode	*No change*
Cause of death clinical cancer group	Cause of death clinical cancer group ICD-9	DeathClinicalCancerGroupCode	DeathClinicalCancerGrp1Code

6.Appendices

6.1. Cancer type and clinical group codes and changes

Table A1: Cancer type ICD-O-3 coding changes between ICD-9 and ICD-10 (version 2019)

| Cancer type | ICD-9 coding | | ICD-10 (2019) coding | |
	ICD-O-3 topography and/or morphology code	Cancer type ICD-9	ICD-O-3 topography and/or morphology code	Cancer type ICD-10
Rectal	C19-C21	C1921	C19, C20	C1920
Anal	C21	N/A	C21	C21
Other and ill-defined	C76	N/A	C26, C39, C76, C422 and (M8890, M9120, M9133),	C237
Retroperitoneum and peritoneum	C48	N/A	C48	C48
Ovarian	C56, C57.0-C57.7	C567	C56, ((C570, C578) and (M8441, M8460, M8461))	C567
Other female genital	C51, C52, C57.8-C57.9	C59	C51, C52, C571-C574, C577, C579, ((C570, C578) and not (M8441, M8460, M8461))	C59
Other central nervous system	C70, C72	C72	C70, C72, C751-C753	C705
Other endocrine gland	C74, C75	C745	C74, C750, C754, C755, C758, C759	C745
Cancer of unknown primary	C26, C39, C48, C76, C80, (C42 and not (M959-M999))	C98	C80	C80
Non-Hodgkin lymphoma	M959, M967-M972, M976	C82	M9590, M9591, M9596, M9597, M9671, M9673, M9675, M9678-M9680, M9684, M9688, M9689, M9690, M9691, M9695, M9698, M9700-M9702, M9705, M9708, M9709, M9712, M9714-M9719, M9724, M9726, M9727 and diagnosis year <= 2010, M9735, M9737, M9738, M9766, (not (C420, C421, C424) and (M9670, M9687, M9728, M9729, M9811, M9823, M9826, M9836, M9837)),	C82

| Cancer type | ICD-9 coding | | ICD-10 (2019) coding | |
	ICD-O-3 topography and/or morphology code	Cancer type ICD-9	ICD-O-3 topography and/or morphology code	Cancer type ICD-10
			(C420, C421, C424, C77) and M9699	
Immunoproliferative	N/A	N/A	(not (C420, C421, C424, C77) and M9699), M9760-M9762, M9764	C88
Multiple myeloma	M973	C8890	M9731-M9734	C90
Acute lymphoblastic leukaemia	M9835-M9837	C910	((C420, C421, C424) and (M9728, M9729, M9811, M9836, M9837)), M9812-M9819, M9835	C910
Chronic lymphocytic leukaemia	N/A	N/A	(C420, C421, C424) and (M9670, M9823)	C911
Other and unspecified lymphoid leukaemias	M982-M983	C919	M9820, M9827, M9831-M9834, M9870, M9940, M9948, ((C420, C421, C424) and (M9687, M9826)	C919
Acute myeloid leukaemia	M9840, M9861, M9866, M9867, M9870-M9874, M9891, M9895-M9897, M991-M993	C920	M9840, M9861, M9865-M9867, M9869, M9871-M9874, M9877-M9879, M9891, M9895-M9898, M9910-M9912, M9920, M9930, M9931, M9984	C920
Chronic myeloid leukaemia	N/A	N/A	M9863, M9875	C921
Other and unspecified myeloid leukaemias	M9860, M9863, M9875, M9876, M9945, M9946, M9963	C929	M9860, M9876	C929
Chronic myelomonocytic leukaemia	N/A	N/A	M9945, M9946	C931
Other and unspecified leukaemias	N/A	N/A	M9800, M9801, M9805-M9809	C945
Other blood cancers	N/A	N/A	M9727 and diagnosis year > 2010, M9740-M9742, M9749-M9751, M9755-M9759, M9965-M9968	C943, C962, C964, C966-C968
Myeloproliferative neoplasms (excluding CML)	N/A	N/A	M9950, M9960-M9964, M9975	D457

| Cancer type | ICD-9 coding | | ICD-10 (2019) coding | |
	ICD-O-3 topography and/or morphology code	Cancer type ICD-9	ICD-O-3 topography and/or morphology code	Cancer type ICD-10
Other lymphatic haematopoietic	(C42, C44, C77) and M959-M997	M95	N/A	N/A
Other specified leukaemias	M9940, M9948	C94	N/A	N/A
Unspecified leukaemias	M980	C95	N/A	N/A

Table A2: Clinical cancer group ICD-O-3 coding changes between ICD-9 and ICD-10 (2019)

| Clinical cancer group (CCG) | CCG ICD-9 | ICD-9 coding | ICD-10 (2019) coding | CCG ICD-10 |
		ICD-O-3 topography and/or morphology code	ICD-O-3 topography and/or morphology code	
Bowel	4	Colon (C18)	Colon (C18)	4
		Rectal (C19-C20)	Rectal (C19-C20)	4
		Anal (C21)	N/A	N/A
Eye	10	Eye (C69)	N/A	N/A
Ill-defined sites and unknown primary sites	14	Other and ill-defined digestive organs (C26)	Other and ill-defined digestive organs (C26)	14
		Other and ill-defined sites in the respiratory system and intrathoracic organs (C39)	Other and ill-defined sites in the respiratory system and intrathoracic organs (C39)	14
		C422 and (M8890, M9120, M9133)	C422 and (M8890, M9120, M9133)	14
		Retroperitoneum and peritoneum (C48)	N/A	N/A
		Other and ill-defined sites (C76)	Other and ill-defined sites (C76)	14
		Cancer unknown primary (C80)	Cancer unknown primary (C80)	14
All other	N/A	N/A	Anal (C21)	15
		N/A	Retroperitoneum and peritoneum (C48)	15
		N/A	Eye (C69)	15

Table A3: Cancer type ICD-10 (2019) with ICD-O-3 and ICD-10 code mapping

Cancer type ICD-10	Name	ICD-O-3 topography and/or morphology code	ICD-10 (2019) code
C00	Lip	C00	C00
C012	Tongue	C01, C02	C01, C02
C036	Mouth	C03-C06	C03-C06
C078	Salivary gland	C07, C08	C07, C08
C0910	Oropharyngeal	C09, C10	C09, C10
C11	Nasopharyngeal	C11	C11
C123	Hypopharyngeal	C12, C13	C12, C13
C14	Other lip, oral cavity and pharyngeal	C14	C14
C15	Oesophageal	C15	C15
C16	Stomach	C16	C16
C17	Small intestine	C17	C17
C18	Colon	C18	C18
C1920	Rectal	C19, C20	C19, C20
C21	Anal	C21	C21
C22	Liver	C22	C22
C234	Gallbladder	C23, C24	C23, C24
C237	Other and ill-defined	C26, C39, C76, C422 and (M8890, M9120, M9133),	C26, C39, C76
C25	Pancreatic	C25	C25
C301	Nasal cavity and sinus	C30, C31	C30, C31
C32	Laryngeal	C32	C32
C334	Lung	C33, C34	C33, C34
C378	Other thoracic	C37, C38	C37, C38
C401	Bone	C40, C41	C40, C41
C43	Melanoma of skin	C44 and M872-M879	C43
C44	Other skin (excl. BCC and SCC)	C44 and not (M805-M811)	C44
C45	Mesothelioma	M905	C45
C46	Kaposi's sarcoma	M9140	C46

Cancer type ICD-10	Name	ICD-O-3 topography and/or morphology code	ICD-10 (2019) code
C479	Connective tissue, peripheral nerves	C47, C49	C47, C49
C48	Retroperitoneum and peritoneum	C48	C48
C50	Breast	C50	C50
C53	Cervical	C53	C53
C545	Uterine	C54, C55	C54, C55
C567	Ovarian	C56, ((C570, C578) and (M8441, M8460, M8461))	C56, (C570, C578 (with morphologies 8441, 8460, 8461))
C58	Placental	C58	C58
C59	Other female genital	C51, C52, C571-C574, C577, C579, ((C570, C578) and not (M8441, M8460, M8461))	C51, C52, C57 (excluding C570, C578 (with morphologies 8441, 8460, 8461))
C61	Prostate	C61	C61
C62	Testicular	C62	C62
C6360	Other male genital	C63, C60	C63, C60
C648	Kidney	C64-C66, C68	C64-C66, C68
C67	Bladder	C67	C67
C69	Eye	C69	C69
C705	Other central nervous system	C70, C72, C751-C753	C70, C72, C751-C753
C71	Brain	C71	C71
C73	Thyroid	C73	C73
C745	Other endocrine gland	C74, C750, C754, C755, C758, C759	C74, C750, C754, C755, C758, C759
C80	Cancer of unknown primary	C80	C80
C81	Hodgkin lymphoma	M9650-M9655, M9659, M9661-M9665, M9667	C81
C82	Non-Hodgkin lymphoma	M9590, M9591, M9596, M9597, M9671, M9673, M9675, M9678-M9680, M9684, M9688, M9689, M9690, M9691, M9695, M9698, M9700-M9702, M9705, M9708, M9709, M9712, M9714-M9719, M9724, M9726, M9727 and diagnosis year <= 2010, M9735, M9737, M9738, M9766, (not (C420, C421, C424) and (M9670, M9687,	C82-C86

Cancer type ICD-10	Name	ICD-O-3 topography and/or morphology code	ICD-10 (2019) code
		M9728, M9729, M9811, M9823, M9826, M9836, M9837)), (C420, C421, C424, C77) and M9699	
C88	Immunoproliferative	(not (C420, C421, C424, C77) and M9699), M9760-M9762, M9764	C88
C90	Multiple myeloma	M9731-M9734	C90
C910	Acute lymphoblastic leukaemia	((C420, C421, C424) and (M9728, M9729, M9811, M9836, M9837)), M9812-M9819, M9835	C910
C911	Chronic lymphocytic leukaemia	(C420, C421, C424) and (M9670, M9823)	C911
C919	Other and unspecified lymphoid leukaemias	M9820, M9827, M9831-M9834, M9870, M9940, M9948, ((C420, C421, C424) and (M9687, M9826)	C913-C919, C947
C920	Acute myeloid leukaemia	M9840, M9861, M9865-M9867, M9869, M9871-M9874, M9877-M9879, M9891, M9895-M9898, M9910-M9912, M9920, M9930, M9931, M9984	C920, C923-C928, C930, C940, C942, C944
C921	Chronic myeloid leukaemia	M9863, M9875	C921
C929	Other and unspecified myeloid leukaemias	M9876, M9860	C922, C929
C931	Chronic myelomonocytic leukaemia	M9945, M9946	C931, C933
C945	Other and unspecified leukaemias	M9800, M9801, M9805-M9809	C950, C959
C96	Other blood cancers	M9727 and diagnosis year > 2010, M9740-M9742, M9749-M9751, M9755-M9759, M9965-M9968	C943, C962, C964, C966-C968
D457	Myeloproliferative neoplasms (excluding CML)	M9950, M9960-M9964, M9975	D45, D471, D473-D475
D46	Myelodysplasia	M9980, M9982, M9983, M9985- M9987, M9989, M9991-M9993	D46
0006	Non-cancer death	N/A	N/A
0007	Unknown cause of death	N/A	N/A
-1	Not available	N/A	N/A

Table A4: Clinical cancer group ICD-10 with ICD-10 (2019) code mapping

Please see Appendix "Table A3: Cancer type ICD-10" for ICD-O-3 code mapping.

Clinical cancer group ICD-10	Name	ICD-10 (2019) code
1	Skin	Lip (C00)
		Melanoma of skin (C43)
		Other skin excl. BCC and SCC (C44)
		Kaposi's sarcoma (C46)
2	Head and neck	Tongue (C01, C02)
		Mouth (C03-C06)
		Salivary gland (C07, C08)
		Oropharyngeal (C09, C10)
		Nasopharyngeal (C11)
		Hypopharyngeal (C12, C13)
		Other oral cavity and pharyngeal (C14)
		Nasal cavity and sinus (C30, C31)
		Laryngeal (C32)
3	Upper gastrointestinal	Oesophageal (C15)
		Stomach (C16)
		Small intestinal (C17)
		Liver (C22)
		Gallbladder (C23, C24)
		Pancreatic (C25)
4	Bowel	Colon (C18)
		Rectal (C19, C20)
5	Respiratory	Lung (C33, C34)
		Other thoracic (C37, C38)
		Mesothelioma (C45)
6	Bone and connective tissue	Bone (C40, C41)
		Connective tissue, peripheral nerves (C47, C49)
7	Breast	Breast (C50)
8	Urogenital	Prostate (C61)
		Testicular (C62)

Clinical cancer group ICD-10	Name	ICD-10 (2019) code
		Other male genital (C63, C60)
		Kidney (C64-C66, C68)
		Bladder (C67)
9	Gynaecological	Cervical (C53)
		Uterine (C54, C55)
		Ovarian (C56, (C570, C578 (with morphologies 8441, 8460, 8461)))
		Placental (C58)
		Other female genital (C51, C52, C57 (excluding C570, C578 (with morphologies 8441, 8460, 8461)))
10	N/A	N/A
11	Neurological	Brain (C71)
		Other central nervous system (C70, C72, C751-C753)
12	Thyroid and other endocrine	Thyroid (C73)
		Other endocrine glands (C74, C750, C754, C755, C758, C759)
13	Blood cancers	Hodgkin lymphoma (C81)
		Non-Hodgkin lymphoma (C82-C86)
		Immunoproliferative (C88)
		Multiple myeloma (C90)
		Acute lymphoblastic leukaemia (C910)
		Chronic lymphocytic leukaemia (C911)
		Other and unspecified lymphoid leukaemias (C913-C919, C947)
		Acute myeloid leukaemia (C920, C923-C928, C930, C940, C942, C944)
		Chronic myeloid leukaemia (C921)
		Other and unspecified myeloid leukaemias (C922, C929)
		Chronic myelomonocytic leukaemia (C931, C933)
		Other and unspecified leukaemias (C950, C959)
		Other blood cancers (C943, C962, C964, C966-C968)

Clinical cancer group ICD-10	Name	ICD-10 (2019) code
		Myeloproliferative neoplasms (excl. CML) (D45, D471, D473-D475)
		Myelodysplasia (D46)
14	Ill-defined sites and unknown primary sites	Other and ill-defined digestive organs (C26)
		Other and ill-defined sites in the respiratory system and intrathoracic organs (C39)
		Other and ill-defined sites (C76)
		Cancer of unknown primary (C80)
15	All other	Anal (C21)
		Retroperitoneum and peritoneum (C48)
		Eye (C69)

Table A5: Cancer type ICD-9 with ICD-O-3 code mapping

Cancer type ICD-9	Name	ICD-O-3 topography and/or morphology code
C00	Lip	C00
C012	Tongue	C01, C02
C036	Mouth	C03-C06
C078	Salivary glands	C07, C08
C0910	Oropharyngeal	C09, C10
C11	Nasopharyngeal	C11
C123	Hypopharyngeal	C12, C13
C14	Other oral cavity & pharyngeal	C14
C15	Oesophageal	C15
C16	Stomach	C16
C17	Small intestine	C17
C18	Colon	C18
C1921	Rectal	C19-C21
C22	Liver	C22
C234	Gallbladder	C23, C24
C25	Pancreatic	C25
C301	Nasal & sinus	C30, C31
C32	Laryngeal	C32

Cancer type ICD-9	Name	ICD-O-3 topography and/or morphology code
C334	Lung	C33, C34
C378	Other thoracic	C37, C38
C401	Bone	C40, C41
C43	Melanoma of skin	C44 and M872-M879
C44	Other skin (excl. BCC & SCC)	C44 and not (M805-M811)
C45	Mesothelioma	M905
C46	Kaposi's sarcoma	M914
C479	Connective tissue, peripheral nerves	C47, C49
C50	Breast	C50
C53	Cervical	C53
C545	Uterine	C54, C55
C567	Ovarian	C56, C57.0-C57.7
C58	Placental	C58
C59	Other female genital	C51, C52, C57.8-C57.9
C61	Prostate	C61
C62	Testicular	C62
C6360	Other male genital	C60, C63
C648	Kidney	C64-C66, C68
C67	Bladder	C67
C69	Eye	C69
C71	Brain	C71
C72	Other central nervous system	C70, C72
C73	Thyroid	C73
C745	Other endocrine glands	C74, C75
C81	Hodgkin lymphoma	M965-M966
C82	Non-Hodgkin lymphoma	M959, M967-M972, M976
C8890	Multiple myeloma	M973
C910	Acute lymphoblastic leukaemia	M9835-M9837
C919	Other and unspecified lymphoid leukaemia	M982-M983
C920	Acute myeloid leukaemia	M9840, M9861, M9866, M9867, M9870-M9874, M9891, M9895-M9897, M991-M993

Cancer type ICD-9	Name	ICD-O-3 topography and/or morphology code
C929	Other and unspecified myeloid leukaemia	M9860, M9863, M9875, M9876, M9945, M9946, M9963
C94	Other specified leukaemia	M9940, M9948
C95	Unspecified leukaemia	M980
C98	Cancer of unknown primary	Other and ill-defined digestive organs (C26)
		Other and ill-defined sites in the respiratory system and intrathoracic organs (C39)
		Hematopoietic and reticuloendothelial systems (C42 and not M959-M999)
		Retroperitoneum and peritoneum (C48)
		Other and ill-defined sites (C76)
		Unknown primary site (C80)
M95	Other lymphatic haematopoietic	(C42, C44, C77) and M959-M997
M96	Myelodysplasia	(C42, C77) and M998-M999
0006	Non-cancer death	N/A
0007	Unknown cause of death	N/A
-1	Not available	N/A

Table A6: Clinical cancer group ICD-9 with ICD-O-3 code mapping

Clinical cancer group ICD-9	Name	ICD-O-3 topography and/or morphology code
1	Skin	Lip (C00)
		Melanoma of the skin (C44 and M872-M879)
		Kaposi's sarcoma (M914)
2	Head and neck	Tongue (C01, C02)
		Mouth (C03-C06)
		Salivary gland (C07, C08)
		Oropharyngeal (C09, C10)
		Nasopharyngeal (C11)
		Hypopharyngeal (C12, C13)
		Other oral cavity and pharyngeal (C14)
		Nasal, sinus (C30, C31)
		Laryngeal (C32)
3	Upper gastrointestinal	Oesophageal (C15)
		Stomach (C16)
		Small intestinal (C17)
		Liver (C22)
		Gallbladder (C23, C24)

Clinical cancer group ICD-9	Name	ICD-O-3 topography and/or morphology code
		Pancreatic (C25)
4	Bowel	Colon (C18)
		Rectal (C19-C21)
5	Respiratory	Lung (C33, C34)
		Other thoracic (C37, C38)
		Mesothelioma (M905)
6	Bone and connective tissue	Bone (C40, C41)
		Connective tissue, peripheral nerves (C47, C49)
7	Breast	Breast (C50)
8	Urogenital	Prostate (C61)
		Testicular (C62)
		Kidney (C64-C66, C68)
		Bladder (C67)
		Other male genital (C60, C63)
9	Gynaecological	Cervical (C53)
		Uterine (C54, C55)
		Ovarian (C56, C57.0-C57.7)
		Placental (C58)
		Other female genital (C51, C52, C57.8-C57.9)
10	Eye	Eye (C69)
11	Neurological	Brain (C71)
		Central nervous system (C70, C72)
12	Thyroid and other endocrine	Thyroid (C73)
		Other endocrine glands (C74, C75)
13	Blood cancers	Note: Logic is applied in order shown
		Hodgkin lymphoma (M965-M966)
		Non-Hodgkin lymphoma (M959, M967-M972, M976)
		Acute lymphoblastic leukaemia (M9835-M9837)
		Other lymphoid leukaemia (M982-M983)
		Acute myeloid leukaemia (M9840, M9861, M9866, M9867, M9870-M9874, M9891, M9895-M9897, M991-M993)
		Other myeloid leukaemia (M9860, M9863, M9875, M9876, M9945, M9946, M9963)
		Other specified leukaemia (M9940, M9948)
		Unspecified leukaemia (M980)
		Multiple myeloma (M973)
		Other lymphoid haematopoietic ((C42, C44, C77) and M959-M997)
		Myelodysplasia ((C42, C77) and M998-M999)

Clinical cancer group ICD-9	Name	ICD-O-3 topography and/or morphology code
14	Cancer unknown primary	Other and ill-defined digestive organs (C26)
		Other and ill-defined sites in the respiratory system and intrathoracic organs (C39)
		Hematopoietic and reticuloendothelial systems (C42 and not (M959-M999))
		Retroperitoneum and peritoneum (C48)
		Other and ill-defined sites (C76)
		Unknown primary site (C80)
15	Other skin	Other skin (excl. BCC & SCC) (C44 and not (M805-M811))
98	Unknown cause of death	Non-cancer death (0006)
		Unknown cause of death (0007)
-1	Not available	Not available (-1)

7.Glossary

Abbreviation	Explanation
ABS	Australian Bureau of Statistics
AIHW	Australian Institute of Health and Welfare
ASGS	Australian Statistical Geography Standard
CINSW	Cancer Institute NSW
LHD	Local health district
LGA	Local government area
NDI	National Death Index
SA1	Statistical Area 1

8.References

1. Australian Institute of Health and Welfare. *Cancer data in Australia 2024*, August release. Available at: Cancer data in Australia, List of cancers available within this report - Australian Institute of Health and Welfare (Accessed September 2024).

2. Victorian Cancer Registry. *Cancer in Victoria, 2022.* Cancer Council Victoria, 2023. Available at: https://www.cancervic.org.au/research/vcr/annual-report-2022 (Accessed August 2024).

3. Cancer Council Queensland. *Queensland Cancer Statistics Online (QCSOL), 2021.* Available at: https://cancerqld.org.au/research/queensland-cancer-statistics/queensland-cancer-statistics-online-qcsol/methodology/#14 (Accessed August 2024).

Cancer Institute NSW

Level 4, 1 Reserve Road,
St Leonards, NSW 2065

Locked Bag 2030
St Leonards NSW 1590

T: (02) 8374 5600
E: information@cancer.nsw.gov.au
W: cancer.nsw.gov.au